Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9%
M&A / Property

Vireo Growth Inc. Announces Effectiveness of Management Services Agreement with PharmaCann Inc.

Vireo’s M&A Blitz Meets Dilution Reality as NY Partnership Signals Regulatory Compliance Over Growth

Executive Summary
  • Vireo Growth Inc. entered a strategic partnership with Ace Venture of NY, LLC, transferring a 51% ownership stake in Vireo Health of New York, LLC to Ace.
  • Vireo retains a 49% minority stake and will continue providing compliance, product quality, and operational support to the newly structured entity.
  • Governance will be shared, with Vireo CEO John Mazarakis and Ace founder Steven Acevedo serving on the board of managers.
  • The transaction is positioned as creating New York’s first scaled social-equity-owned cannabis operator, aligning with state regulatory mandates that prioritize minority- and women-owned business licenses.
  • No cash consideration, earn-outs, or specific financial terms were disclosed in the release.
Material Impact
  • The announcement is structurally significant for New York market access but financially immaterial to Vireo’s consolidated balance sheet.
  • Ceding majority control (51%) to a social equity partner is a standard compliance maneuver in New York’s highly restrictive licensing environment. It likely secures Vireo’s operational footprint in the state while mitigating regulatory rejection risk.
  • Vireo’s 49% stake means it will only recognize a minority share of NY subsidiary cash flows, limiting near-term revenue contribution from this specific asset.
  • The deal does not provide new capital, reduce debt, or alter the company’s aggressive M&A trajectory. It is an expected, incremental step rather than a catalyst.
VREO · Price
Company Overview
  • Vireo Growth is a U.S.-focused cannabis multi-state operator with a retail-heavy footprint spanning 10 states post-Eaze acquisition.
  • Flagship operations include vertically integrated cultivation, manufacturing, and a dense retail/delivery network (160+ dispensaries, ~800,000 sq ft of cultivation/production capacity).
  • The company’s strategy is aggressively acquisitive, targeting distressed or undervalued assets to scale market share rapidly.
  • Recent integrations include Deep Roots, Proper, Wholesome, Schwazze, Eaze, and pending PharmaCann and Hawthorne assets.
Read the original news release →

More from Vireo Growth Inc.